Veryan Medical was incorporated in June 2003 as a spin-out company from Imperial College, London. The company is an ISO9001 accredited designer and manufacturer of surgeon-choice implantable vascular devices.
Veryan Medical has received total equity investment to date of £3.1 million, and has option agreements in place for £5.2 million further investment. Its shareholders are Nikko Principal Investments Ltd, Imperial College Innovations Ltd, Oxford Gateway Fund, National Endowment for Science and Arts (NESTA), management, and founders.
The Company is run by a first class management team, and directed by a highly experienced board of directors:
Chas Taylor (Chairman):
Previously CEO of Mednova, a stent development company, which he subsequently sold to Abbott Vascular.
Philip Birch (CEO):
Successful track record for building early stage technology companies.
Paul Gilson
(Development Director): Previously VP R&D for Bard, then CSO of Mednova.
Colin Caro
(Research Director): Technology inventor and world authority on physiological flow mechanics.
Nick Cheshire
(Medical Director): Leading European vascular surgeon.
Alan Edwards:
Previously MD Cardiotech, then CEO Credent Vascular
Valerie Marshall:
Corporate financier, previously Scottish Enterprise and 3i
Vascular disease remains the main cause of premature death in industrialized society. Veryan Medical has used its unique understanding of the link between blood flow mechanics and vascular disease to develop a series of medical devices focused on specific unmet needs in vascular surgery.
The SwirlGraftTM
Veryan Medical’s first product, the SwirlGraftTM has already been awarded US and European regulatory approvals. It has undergone highly successful pre-clinical testing, and is now also proving successful in European clinical trials as an arterio-venous access graft for kidney dialysis patients.
Further valuable products are currently under development, including the SwirlFlowTM endovascular stent to address peripheral vascular disease, and the SwirlGripTM endograft for the treatment of aneurysms and injured vessels.
